Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Therapy-induced small-cell disease: from mouse to man and back.

Grabowska MM, Matusik RJ.

Nat Rev Urol. 2018 Nov;15(11):662-663. doi: 10.1038/s41585-018-0084-z. No abstract available.

PMID:
30177737
2.

Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo.

Yang S, Jiang M, Grabowska MM, Li J, Connelly ZM, Zhang J, Hayward SW, Cates JM, Han G, Yu X.

Oncotarget. 2016 Oct 25;7(43):70404-70419. doi: 10.18632/oncotarget.11879.

3.

Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.

Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R.

Oncotarget. 2016 Sep 20;7(38):61955-61969. doi: 10.18632/oncotarget.11326.

4.

NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Aug;76(11):1004-18. doi: 10.1002/pros.23195. Epub 2016 May 16.

5.

NF-κB and androgen receptor variant expression correlate with human BPH progression.

Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Apr;76(5):491-511. doi: 10.1002/pros.23140. Epub 2015 Dec 28.

6.

Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.

Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ.

Endocrinology. 2016 Mar;157(3):1094-109. doi: 10.1210/en.2015-1312. Epub 2015 Dec 17.

7.

Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.

Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA 3rd, Smith JA Jr, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ.

Am J Pathol. 2015 May;185(5):1385-95. doi: 10.1016/j.ajpath.2015.01.014.

8.

SOX2 expression in the developing, adult, as well as, diseased prostate.

Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):301-9. doi: 10.1038/pcan.2014.29. Epub 2014 Aug 5.

9.

FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.

DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ.

Lab Invest. 2014 Jul;94(7):726-39. doi: 10.1038/labinvest.2014.64. Epub 2014 May 19.

10.

NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.

Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH, Ahn JM, Raj GV, Piston DW, Gronostajski RM, Matusik RJ.

Mol Endocrinol. 2014 Jun;28(6):949-64. doi: 10.1210/me.2013-1213. Epub 2014 May 6.

11.

Mouse models of prostate cancer: picking the best model for the question.

Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ.

Cancer Metastasis Rev. 2014 Sep;33(2-3):377-97. doi: 10.1007/s10555-013-9487-8. Review.

12.

Soluble E-cadherin: more than a symptom of disease.

Grabowska MM, Day ML.

Front Biosci (Landmark Ed). 2012 Jan 1;17:1948-64. Review.

13.

EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.

Grabowska MM, Sandhu B, Day ML.

Cell Signal. 2012 Feb;24(2):532-8. doi: 10.1016/j.cellsig.2011.10.004. Epub 2011 Oct 14.

Supplemental Content

Loading ...
Support Center